Woman reveals horrifying botched nose after popular plastic surgery treatment goes wrong
On Reddit, the young woman took to the popular 'plastic surgery' thread to share a picture of her misshaped facial feature.
The snapshot caught something snaking down the bridge of her nose in a seemingly wiggly lump as the patient struck a worried expression.
'Just wanted everyone to know this can happen and maybe PDO [Polydioxanone] threads in the nose is a no-no,' she wrote under her jarring image.
Polydioxanone threads have become a popular option for people wanting a straighter and more defined nose, per Moksha Aesthetics.
The threads are inserted through the tip of the nose and provide a lift at the bridge.
They are supposed to dissolve within six to 12 months and stimulate the production of collagen to produce a more defined nose bridge.
If the threads aren't properly secured, migration and asymmetry is possible - and the young woman's nose is an example.
On Reddit, the young woman took to the popular 'plastic surgery' thread to share a picture of her misshaped facial feature
People in the comments were shocked by the surgery and questioned what had happened.
Someone wrote: 'Girl, what the...?? What happened?? How does this happen?? What was this even for?'
'I was told it would just give me the appearance of a nose job without an invasive surgery… haha worst decision ever,' she responded.
She went on to explain that, ironically, she now 'might need surgery to get them out.'
Another person wrote about their close encounter with PDO threads.
'Omg, you need to give us an update when you figure out how to get it fixed...
'I almost got this done, and the nurse injector told me not to because this could happen. So glad I didn't. I hope surgery isn't necessary for you!!' they shared.
Someone penned: 'Doing the Lord's work, showing how bad threads can be! Sorry this happened to you, and I hope they can get it out...
'That is insane, and I'm so fearful that I'll have scar tissue in my nose now,' a person said.
'I'm so sorry. I hope you get this fixed soon, and THANK YOU for sharing and spreading awareness,' a comment read.
The woman later revealed in a comment that she got the procedure done in Bali, Indonesia.
'Terrible mistake on my end,' she wrote.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 hours ago
- Daily Mail
Menopause made my hair fall out. Then I discovered a new hair-loss solution. This is the secret ALL midlife women need to know
For me, midlife has brought various indignities, as well as many joys. But standing over a sink to count the number of hairs that had come out in my brush one morning has to be among the more distressing aspects. For the record, it was 201. And why was I counting them? Because I'd searched 'how to tell if your hair is falling out' online – and according to Dr Google, anything over 100 strands was a cause for concern.
The Independent
4 hours ago
- The Independent
WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs
WeightWatchers was slower to adapt to the emergence of anti-obesity jabs than rivals, its boss has admitted, as the 62-year-old brand strives to catch up with rapidly evolving attitudes towards weight loss. Tara Comonte, chief executive of the US-based business, said it had a lot of work to do after going through a 'reset'. WeightWatchers recently announced it had emerged from bankruptcy after writing off a portion of the 1.15 billion US dollar (£860 million) debt on its balance sheet. It came as the business was competing with the emergence of GLP-1s – the scientific term for weight loss jabs, which work by reducing food cravings – and a new wave of apps and advice spreading on social media. Ms Comonte told the PA news agency that it 'wasn't as quick to medical weight loss solutions' as some other firms in the US, notably so-called 'telehealth' businesses that offer healthcare remotely. WeightWatchers, which runs some 20,000 workshops each month globally, is now 'at the beginning of the journey' towards forging a new place in the industry and meeting demand from current and future members, Ms Comonte said. 'This whole industry is going through somewhat of a reset and we have exciting work to do,' she told the PA news agency. 'This is a moment where, possibly more than ever before, people are talking about weight, and weight health… where people are seeking more education than ever before, and there are more voices than ever before.' Ms Comonte said the brand was known for 'trust and science' and it was important to harness that 'as there are more and more voices in the ecosystem'. WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app. It forms part of its efforts to muscle into the market by offering behavioural strategies and community-based support to people using or coming off the medication. 'There's no 'us and them' anymore,' Ms Comonte told PA, hitting back at weight loss jabs often being pitted as rivals to its model. Dr Kim Boyde, WeightWatchers' newly appointed chief medical officer, said not all its members will want or need weight loss medication – but stressed that it was 'imperative' the programme offers it to those that might benefit. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.
Reuters
5 hours ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
